Close
Digital Health & Ai Innovation summit 2026
Medical Taiwan 2026

Engineered Bacteria Effectively Target Tumors, Enabling Tumor Imaging Potential In Mice

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media PackNow

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

UK Medical Device Testing Jumps 17%,...

Clinical investigations of medical devices in the UK reached...

Medtronic Secures FDA PMA for Infuse...

Medtronic announced that it has secured FDA premarket approval...

Medica Axon Diagnostics Merger Expands UK...

Teleradiology provider Medica Group has agreed to integrate Axon...
Tumor-targeted bioluminescent bacteria have been shown for the first time to provide accurate 3D images of tumors in mice, further advancing the potential for targeted cancer drug delivery, according to a study published in the Jan. 25 issue of the online journal PLoS ONE. 
 
The specially engineered probiotic bacteria, like those found in many yoghurts, were intravenously injected into mice with tumors, after which the researchers took full body bioluminescent images. The 3D images revealed information about the number and location of the bacteria, to the level of precisely revealing where within the tumour the bacteria were living, providing much more information on the interaction of bacteria and tumors than was previously available using similar two-dimensional imaging methods. 
According to the authors, led by Mark Tangney of University College Cork in Ireland, "before now, researchers used luminescence to provide an approximation of where a test organism was within the body, and would then follow up with multiple further experiments using different techniques to try to find a precise location". This new research suggests that such bacteria can be engineered to contain diagnostic or therapeutic agents that would be produced specifically within the tumor for targeted treatment. 

Latest stories

Related stories

UK Medical Device Testing Jumps 17%, AI and Neurotech Lead

Clinical investigations of medical devices in the UK reached...

Medtronic Secures FDA PMA for Infuse Bone Graft in TLIF

Medtronic announced that it has secured FDA premarket approval...

Medica Axon Diagnostics Merger Expands UK Clinical Reporting

Teleradiology provider Medica Group has agreed to integrate Axon...

Sutter Health Integrates AI Decision Support in Epic EHR

Sutter Health is integrating artificial intelligence-powered decision support technology...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »